Drug intelligence / Profile preview

Hydroxiram D

Development stage: Unknown
Lead developer: Errekappa Euroterapici
Modality: Small Molecules
Administration: Oral

Overview

Hydroxiram D is a food for special medical purposes (FSMP) formulated for the dietary management of individuals with protein malnutrition, sarcopenia, or metabolic fragility, particularly those with hepatic or renal disease, post-stroke recovery, or post-major surgery. It is a combination product containing branched-chain amino acids (L-leucine, L-isoleucine, and L-valine), calcium beta-hydroxy-beta-methylbutyrate (calcium HMB), vitamin D3 (cholecalciferol), and zinc oxide. The formulation is enriched with natural thickeners (xanthan gum and glucomannnan) to allow gelation upon contact with water, making it suitable for dysphagic patients or those with swallowing difficulties.

Brand names: Hydroxiram D
Other names: HIDROXIRAM DHydroxiram® D

Targets

mTOR (Mammalian target of rapamycin kinase)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Hydroxiram D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hydroxiram D.